

**PUSH BACK EARLY.
EXTEND LIFE.¹**

**ERLEADA[®]:
FOR ALL mHSPC^{1,a,b} &
nmCRPC^{2,c} PATIENTS**



¹ Chi KN et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol. 2021 Jul 10; 39(20):2294–2303. ² Smith MR et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021 Jan; 79(1):150–158. DOI: 10.1016/j.eururo.2020.08.011. Epub 2020 Sep 6.

^a Under ADT; TITAN study: HR = 0.65; 95% CI: 0.53–0.79; p < 0.0001. ^b Regardless of extent or risk of disease (high-/low-volume, Gleason score, newly/previously diagnosed) or prior therapy (docetaxel, ADT, local therapies). ^c Under ADT, with PSA doubling time ≤ 10 months and without distant metastases.

References upon request by Janssen-Cilag AG.

Erleada[®] apalutamid 60 mg film-coated tablets. **I:** In combination with androgen deprivation therapy (ADT) for adults with either non-metastatic, castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastasis, particularly where PSADT ≤ 10 months, or metastatic, hormone-sensitive prostate cancer (mHSPC). **D:** 240 mg (4 x 60 mg tablets), administered orally, once daily; note dosage modifications. **CI:** Hypersensitivity to the active substance or to one of the excipients depending on the composition, and women with no indication or who are pregnant or of childbearing potential. **WP:** caution in patients at risk or with a history of ischaemic heart disease, recent cardiovascular disease, seizures, falls, fractures, QT prolongation, and severe cutaneous adverse reactions; men and women should use effective contraception (as fetal development abnormalities may occur). **AR:** Very common (≥ 1/10): arthralgia, diarrhoea, fatigue, fractures, weight loss, skin rash, flushing, hypertension and falls. **Common** (≥ 1/100 to < 1/10): Dysgeusia, hypercholesterolaemia, hypertriglyceridaemia, hypothyroidism, ischaemic heart disease, muscle spasms and pruritus. **DI:** Medicinal products that prolong the QT interval, CYP3A4 and CYP2C8 inhibitors or inducers and substrates of BCRP, CYP3A4, CYP2B6, CYP2C8/9/19, OAT3, OATP1B1, P-gp and UGT. **Packaging:** blister pack containing 112 film-coated tablets (4x28). **Prescribing category:** B; detailed information: www.swissmedinfo.ch. **Marketing authorisation holder:** Janssen-Cilag AG, Gubelstrasse 34, 6300 Zug. (CH_CP-327595)

THE POWER OF **PURPOSE[®]**



We would like to thank all the companies that have supported us in recent years!

Cooperation partner



Main sponsor



Sponsor



2. UROART Symposium

«Novel strategies for M1 prostate cancer prevention»

January 12th, 2024

Universitätsspital Basel, Klinik für Urologie

www.uro-art.ch

Foreword

Dear Ladies and Gentlemen, We would like to invite you to our **2nd UROART Symposium on 12th January 2024 in Basel** at the Universitätsspital.

In December 2022, the council of the European Union announced the intention to consider extending targeted cancer screening beyond breast, colorectal and cervical cancer to include prostate cancer. The recommendation encourages countries to evaluate the feasibility and effectiveness of the implementation of organized screening programs for prostate cancer to reduce the burden of the disease and its mortality through early detection, based on the latest available scientific developments and evidence. However, the case is not so clear with conclusive evidence still out there; while data from the Unites States reveal an upsurge in advanced and metastatic prostate cancer cases after the USPSTF recommendation against PSA screening, recent results of the PROTECT trial question the survival benefit of whole gland treatment in localized prostate cancer. Therefore, we are more than delighted to welcome some the most renewed experts for early detection of prostate cancer at the second UROART event in Basel for scientific exchange and debate on this emerging topic. To screen or not to screen will be the question during our morning session.

In the second half of the day, we will focus on the optimal management of men with very high-risk or locally advanced prostate cancer whose disease were most likely not detected early. The aim in these men is avoiding metastatic disease while preserving quality of life. An excellent panel of interdisciplinary speakers will give state of the art lectures on diagnostic pathways and treatment options in this population. We are very much looking forward to welcoming you at our second UROART event in Basel.

Prof. Helge Seifert
Head of Urology

PD Dr. Ashkan Mortezaei
Scientific Program Director

Thomas J. Lautenschlager
Senior Healthcare Expert

Program

- 8:45 **Welcome speech**
Prof. H. Seifert
- 8:55 **Prostate Cancer in Switzerland**
PD Dr. A. Mortezaei
On behalf of the Swiss Prostate Cancer Screening Working Group
- Session 1 – Early detection**
- Chairs:** *Prof. Per Anders Abrahamsson (Lund University) and Prof. Cyrill Rentsch (Universitätsspital Basel)*
- 9:00 **Prime time for organised, risk-adapted prostate cancer screening - Impact of the EU recommendations**
Prof. Hein Van Poppel, Chair of the EAU Policy Office
- 9:30 **Prostate cancer screening, the current status in Europe: first results from the PRAISE-U project**
Prof Monique Roobol, Erasmus Medical Centre Rotterdam
- 10:00 **Early detection in the context of ProtecT: more harm than good?**
Prof. Freddie Hamdy, Nuffield Department of Surgical Sciences, University of Oxford
- 10:30 **Coffee break**
- 11:00 **Novel strategies for prostate cancer screening – the Stockholm trials**
Ass. Prof. Tobias Nordström, PhD, Danderyd Sjukhus / Karolinska Institutet Stockholm
- 11:30 **Risk adapted PSA screening - first results from the PROBASA trial**
Prof. Peter Albers, Heinrich-Heine-University Düsseldorf
- 12:00 **Discussion**
- 12:15 **Lunch**
- Session 2 – Treating high risk non-metastatic prostate cancer**
- Chairs:** *Prof. Derya Tilki (Martini Klinik Hamburg) and Prof. Frank Stenner (Universitätsspital Basel)*
- 13:15 **Role of PSMA PET CT for local staging of prostate cancer**
Prof. Irene Burger, Kantonsspital Baden
- 13:45 **Identifying the optimal candidates for pelvic lymph node dissection during prostatectomy**
Prof. Alberto Briganti, Università Vita-Salute San Raffaele, Milan
- 14:15 **Robotic prostatectomy for high risk locally-advanced prostate cancer: techniques and outcomes from the highest volume UK centre**
Prof. Prabhakar Rajan, University College London Hospitals
- 14:45 **Coffee break**
- 15:15 **Surgery or radiotherapy for locally advanced prostate cancer**
Prof. Piet Ost, Ghent University
- 15:45 **Treatment intensification for high-risk, locally advanced and N+ prostate cancer**
Prof. Silke Gillessen, Oncology Institute of Southern Switzerland, EOC, Bellinzona
- 16:15 **Discussion**

* Program subject to minor changes

Information & Registration

Event date:
Friday, 12 January 2024

Credits:
8 SGU

Participation fee online registration:
CHF 135.- incl. breaks and standing lunch
CHF 85.- for residents and researchers

Participation fee Fax or mail registration:
CHF 140.- incl. breaks and standing lunch

Contact event registrations:
anmeldung@med-management.ch

Postal address:
UROART
c/o LH Medical Management GmbH
Postfach 96
6000 Luzern 6

Registration deadline:
11 Jan. 2024 (box office thereafter)

Venue:
ZLF-Hörsaal Universitätsspital Basel
Hebelstrasse 20
4031 Basel

Contact responsible for the event:
Tanja Reifenrath
tr@med-management.ch

Tel.: +41 79 386 40 40
Fax: +41 (0)61 921 71 76

info@med-management.ch
www.uro-art.ch

Registration online at:
www.uro-art.ch

HCS Health Care Services

GENERALI sanitas

Unsere Anerkennung für Ihre wertvolle Arbeit, die Sie im Gesundheitswesen leisten!

Sichern Sie sich auch als bestehender Kunde bei Sanitas oder Generali ihren Rabatt!